Fulgent Genetics, Inc. cash flow to debt ratio of -1.32K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Fulgent Genetics, Inc.'s free cash flow has decreased 545.09% from $-19.25M last year to $-124.21M, signaling decreasing performance

Fulgent Genetics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Fulgent Genetics, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.01 today, signaling weakened financials

Fulgent Genetics, Inc. has negative EBITDA, making leverage ratio unreliable

Fulgent Genetics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Fulgent Genetics, Inc.'s profit margin has decreased (52.93%) in the last year from -15.07% to -23.04%, signaling decreasing performance

Fulgent Genetics, Inc.'s short-term assets of $550.49M exceed its short-term liabilities of $84.97M

Fulgent Genetics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Fulgent Genetics, Inc.'s return on equity of -6.70%, is lower than 15.00%, indicating bad performance

Fulgent Genetics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Fulgent Genetics, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Fulgent Genetics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Fulgent Genetics, Inc. has negative free cash flow, indicating cash burn

Fulgent Genetics, Inc.'s yearly earnings has decreased 41.69% since last year from $-42.71M to $-60.51M, signaling decreasing performance

Fulgent Genetics, Inc.'s yearly revenue has increased 13.83% since last year from $283.47M to $322.67M, signaling increasing performance

ROIC -8.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Fulgent Genetics, Inc.'s 3-year revenue CAGR of -19.52% is negative, indicating declining revenue over the past 3 years

Fulgent Genetics, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Fulgent Genetics, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Fulgent Genetics, Inc. has insufficient data to evaluate this check.

Fulgent Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fulgent Genetics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Fulgent Genetics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Fulgent Genetics, Inc. is overvalued relative to its fair value price of -18.36 based on Earnings Fair Value model

Fulgent Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fulgent Genetics, Inc. has a price-to-book ratio of 0.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Fulgent Genetics, Inc. has a price-to-sales ratio of 1.97x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue